Skip to content

The effect of lidocaine on the neuroinflammation of patients with colorectal surgery through RAAS system pathway

The effect of lidocaine on the neuroinflammation of patients with colorectal surgery through RAAS system pathway

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055683
Enrollment
Unknown
Registered
2022-01-16
Start date
2022-02-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Control group:Intravenous infusion of equal volume of normal saline

Sponsors

The First People's Hospital of Changde
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Volunteer to participate in this study and have full capacity for civil conduct, and sign the informed consent; 2. Patients who undergo elective laparoscopic radical resection of colorectal cancer in our hospital; 3. Age 18-70 years old, BMI 18-30 kg/m2; 4. Operation time <= 3 hours; 5. The patient has not participated in other drug clinical trials in the past 3 months before enrollment.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to lidocaine or amides; 2. Combined with other important organ dysfunction: including severe liver and kidney dysfunction; brain organic disease, specifically aneurysmal vascular disease or arteriovenous malformation and cerebral hemorrhage; severe hypertension, coronary heart disease, cardiac insufficiency (NYHA >= Grade III), pulmonary hypertension; blood system disease; abnormal coagulation function; severe respiratory system disease; 3. Patients with indoor conduction block; 4. Patients with untreated or undertreated hyperthyroidism; 5. Patients with alcohol or drug dependence or drug abuse history; 6. Patients with epilepsy, mental illness and taking antipsychotic drugs or family hereditary mental illness; 7. People with serious infectious diseases; 8. Other researchers think that they are not suitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Interleukin 6;Interleukin 8;Interleukin-1a;Tumor necrosis factor alpha;

Countries

China

Contacts

Public ContactWang Xianxue

The First People's Hospital of Changde

wxxxzyxy2013@163.com+86 15973666202

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026